PDF(Pubmed)
Abstract：
UNASSIGNED: Laparoscopic sleeve gastrectomy (LSG) has emerged as a valuable treatment for various metabolic disorders, including metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with obesity. Consequently, there is a pressing need to develop noninvasive biomarkers for diagnosing and monitoring disease progression.
UNASSIGNED: This study aimed to evaluate specific biomarkers, including Cytokeratin-18 (CK-18), C-peptide, monocyte to HDL cholesterol ratio (MHR), and MACK-3, in patients with obesity with MAFLD undergoing LSG.
UNASSIGNED: A prospective cohort study on patients with obesity before and 6 months after the LSG procedure.
UNASSIGNED: 70 patients with obesity with confirmed MAFLD, determined by Transient Elastography (TE), were pre- and 6 months postoperatively tested. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), lipid profile, ghrelin, leptin, peptide YY, GLP-1, and liver fibrosis scores, including AST/ALT ratio (AAR), Fibrosis-4 index (FIB-4), and BARD Score were tested.
UNASSIGNED: BMI significantly decreased in all participants, with a % excess weight loss of 62.0% ± 15.4%. TE measurements revealed a significant postoperative reduction from 100% to 87.1% (P = .006). All selected biomarkers showed significant postoperative improvement-a significant association of CK-18 with MAFLD markers, including AAR, FIB-4, and BARD score, were found. MACK-3 had positive associations with FIB-4. C-peptide and MHR showed no association with MAFLD markers. Furthermore, there was a positive correlation between CK-18 and MACK-3 tests and between C-peptide and CK-18 and MACK-3. Additionally, a receiver operating characteristic (ROC) curve was constructed, with CK-18 performing the best, with an estimated area under the curve of 0.863.
UNASSIGNED: Serum CK-18 outperformed other selected biomarkers in predicting and monitoring MAFLD in patients with obesity, suggesting its prospective utility in clinical practice. Further studies are needed to validate the accuracy of the MACK-3 test.
Effect on biomarkers in patients with fatty liver after weight loss surgery A sleeve gastrectomy is an operation when patient have obesity and need to lose weight. This operation help people with obesity who also have fatty liver disease that’s not related to alcohol use. Researchers are looking for simple blood tests to track the disease. In this study, they checked how well 4 of these tests worked before and after the surgery in 70 people. They found that the patients lost a lot of weight and their liver health improved. One test, in particular, called CK-18, was really good at showing these changes. Another test, MACK-3, also showed promise, but more research is needed to be sure. The other 2 tests didn’t seem to be linked to signs of fatty liver disease. This suggests that CK-18 could be a useful tool for doctors to see how patients are doing after this surgery.
UNASSIGNED: This study aimed to evaluate specific biomarkers, including Cytokeratin-18 (CK-18), C-peptide, monocyte to HDL cholesterol ratio (MHR), and MACK-3, in patients with obesity with MAFLD undergoing LSG.
UNASSIGNED: A prospective cohort study on patients with obesity before and 6 months after the LSG procedure.
UNASSIGNED: 70 patients with obesity with confirmed MAFLD, determined by Transient Elastography (TE), were pre- and 6 months postoperatively tested. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), lipid profile, ghrelin, leptin, peptide YY, GLP-1, and liver fibrosis scores, including AST/ALT ratio (AAR), Fibrosis-4 index (FIB-4), and BARD Score were tested.
UNASSIGNED: BMI significantly decreased in all participants, with a % excess weight loss of 62.0% ± 15.4%. TE measurements revealed a significant postoperative reduction from 100% to 87.1% (P = .006). All selected biomarkers showed significant postoperative improvement-a significant association of CK-18 with MAFLD markers, including AAR, FIB-4, and BARD score, were found. MACK-3 had positive associations with FIB-4. C-peptide and MHR showed no association with MAFLD markers. Furthermore, there was a positive correlation between CK-18 and MACK-3 tests and between C-peptide and CK-18 and MACK-3. Additionally, a receiver operating characteristic (ROC) curve was constructed, with CK-18 performing the best, with an estimated area under the curve of 0.863.
UNASSIGNED: Serum CK-18 outperformed other selected biomarkers in predicting and monitoring MAFLD in patients with obesity, suggesting its prospective utility in clinical practice. Further studies are needed to validate the accuracy of the MACK-3 test.
Effect on biomarkers in patients with fatty liver after weight loss surgery A sleeve gastrectomy is an operation when patient have obesity and need to lose weight. This operation help people with obesity who also have fatty liver disease that’s not related to alcohol use. Researchers are looking for simple blood tests to track the disease. In this study, they checked how well 4 of these tests worked before and after the surgery in 70 people. They found that the patients lost a lot of weight and their liver health improved. One test, in particular, called CK-18, was really good at showing these changes. Another test, MACK-3, also showed promise, but more research is needed to be sure. The other 2 tests didn’t seem to be linked to signs of fatty liver disease. This suggests that CK-18 could be a useful tool for doctors to see how patients are doing after this surgery.
摘要：
■腹腔镜袖状胃切除术（LSG）已成为各种代谢紊乱的有价值的治疗方法，包括肥胖患者的代谢功能障碍相关脂肪性肝病（MAFLD）。因此,迫切需要开发用于诊断和监测疾病进展的非侵入性生物标志物.
■本研究旨在评估特定的生物标志物，包括细胞角蛋白-18（CK-18），C-肽，单核细胞与高密度脂蛋白胆固醇比率（MHR），和MACK-3，在接受LSG的MAFLD肥胖患者中。
■一项针对LSG手术前后6个月肥胖患者的前瞻性队列研究。
■70例确诊为MAFLD的肥胖患者，通过瞬态弹性成像(TE)确定，术前和术后6个月进行测试。胰岛素抵抗的稳态模型评估（HOMA-IR），血脂谱,ghrelin,瘦素,肽YY,GLP-1和肝纤维化评分，包括AST/ALT比值（AAR），纤维化-4指数（FIB-4），和BARD评分进行了测试。
■所有参与者的BMI均显着下降，重量损失为62.0%±15.4%。TE测量显示术后显着降低，从100％降至87.1％（P=.006）。所有选定的生物标志物均显示术后明显改善-CK-18与MAFLD标志物的显着关联，包括AAR,FIB-4和BARD得分,被发现了。MACK-3与FIB-4呈正相关。C-肽和MHR显示与MAFLD标志物无关联。此外，CK-18和MACK-3测试之间以及C肽与CK-18和MACK-3之间存在正相关。此外,构建了受试者工作特性(ROC)曲线，CK-18表现最好，曲线下的估计面积为0.863。
■血清CK-18在预测和监测肥胖患者MAFLD方面优于其他选定的生物标志物，表明其在临床实践中的前瞻性实用性。需要进一步的研究来验证MACK-3测试的准确性。
减重手术后对脂肪肝患者生物标志物的影响袖状胃切除术是当患者有肥胖且需要减肥时的手术。这项手术可以帮助患有与饮酒无关的脂肪肝疾病的肥胖者。研究人员正在寻找简单的血液测试来追踪这种疾病。在这项研究中,他们在70人的手术前后检查了其中4项测试的效果。他们发现患者体重减轻了很多，肝脏健康得到了改善。一个测试，特别是,叫做CK-18，非常擅长展示这些变化。另一个测试，MACK-3也显示出希望，但是需要更多的研究来确定。其他两项测试似乎与脂肪肝的症状无关。这表明CK-18可能是医生观察手术后患者情况的有用工具。
■本研究旨在评估特定的生物标志物，包括细胞角蛋白-18（CK-18），C-肽，单核细胞与高密度脂蛋白胆固醇比率（MHR），和MACK-3，在接受LSG的MAFLD肥胖患者中。
■一项针对LSG手术前后6个月肥胖患者的前瞻性队列研究。
■70例确诊为MAFLD的肥胖患者，通过瞬态弹性成像(TE)确定，术前和术后6个月进行测试。胰岛素抵抗的稳态模型评估（HOMA-IR），血脂谱,ghrelin,瘦素,肽YY,GLP-1和肝纤维化评分，包括AST/ALT比值（AAR），纤维化-4指数（FIB-4），和BARD评分进行了测试。
■所有参与者的BMI均显着下降，重量损失为62.0%±15.4%。TE测量显示术后显着降低，从100％降至87.1％（P=.006）。所有选定的生物标志物均显示术后明显改善-CK-18与MAFLD标志物的显着关联，包括AAR,FIB-4和BARD得分,被发现了。MACK-3与FIB-4呈正相关。C-肽和MHR显示与MAFLD标志物无关联。此外，CK-18和MACK-3测试之间以及C肽与CK-18和MACK-3之间存在正相关。此外,构建了受试者工作特性(ROC)曲线，CK-18表现最好，曲线下的估计面积为0.863。
■血清CK-18在预测和监测肥胖患者MAFLD方面优于其他选定的生物标志物，表明其在临床实践中的前瞻性实用性。需要进一步的研究来验证MACK-3测试的准确性。
减重手术后对脂肪肝患者生物标志物的影响袖状胃切除术是当患者有肥胖且需要减肥时的手术。这项手术可以帮助患有与饮酒无关的脂肪肝疾病的肥胖者。研究人员正在寻找简单的血液测试来追踪这种疾病。在这项研究中,他们在70人的手术前后检查了其中4项测试的效果。他们发现患者体重减轻了很多，肝脏健康得到了改善。一个测试，特别是,叫做CK-18，非常擅长展示这些变化。另一个测试，MACK-3也显示出希望，但是需要更多的研究来确定。其他两项测试似乎与脂肪肝的症状无关。这表明CK-18可能是医生观察手术后患者情况的有用工具。
